Kevin Kalinsky is an Oncology physician. ClinicalTrials.gov lists 10 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Research metrics aren't shown for this record. Either we found no confident publication match for this name, or more than one physician shares the matched author record. We'd rather show nothing than someone else's numbers. Why? →
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
161 Fort Washington Avenue, 10th Floor, Room 1069
Columbia University Medical Center
New York, NY 10032
Telephone
212-305-1945Provider last certified this registry record 22 Sept 2020.
Clinical trials
- ProAgio in Combination With Gemcitabine in Patients With Metastatic Triple Negative Breast Cancer
Sponsor: ProDa BioTech, LLC
- Testing Ipatasertib as Potentially Targeted Treatment in Cancers With AKT Genetic Changes (MATCH - Subprotocol Z1K)
Sponsor: National Cancer Institute (NCI)
- Testing AZD5363 as a Potential Targeted Treatment in Cancers With AKT Genetic Changes (MATCH-Subprotocol Y)
Sponsor: National Cancer Institute (NCI)
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
19 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Merck Sharp & Dohme LLCProgram year20255 payments
- PFIZER INC.Program year20259 payments
- Genentech USA, Inc.Program year20252 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
61.5%Aromatase Inhibitor38%Anastrozole55%Letrozole34%Exemestane10%Part D<11 patientsKinase inhibitor20.1%Verzenio45%Ibrance35%Kisqali20%Part D<11 patients+ 1 more class in this area
Sensory organs
15%Corticosteroid15%Dexamethasone100%Part D≥14 patientsNervous system
12.2%Phenothiazine12.2%Prochlorperazine Maleate100%Part D≥24 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
2 NIH research awards on record, funded 2014–2017 per NIH RePORTER. The latest:
- Identifying leptomeningeal metastasis from breast cancer utilizing a novel immunocytochemical microfluidic device
Columbia University Health Sciences
FY2017$80,000R03CA208547 - Identifying leptomeningeal metastasis from breast cancer utilizing a novel immunocytochemical microfluidic device
Columbia University Health Sciences
FY2016$80,000R03CA208547 - Pre-Surgical trial of Metformin and Atorvastatin in Operable Breast Cancer
Columbia University Health Sciences
FY2015$80,000R03CA186931
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Similar KOLs
Other experts from the same institution or the same specialty.
Freddie Bray
Centre National de la Recherche Scientifique
Jacques Ferlay
Centre international de recherche sur le cancer
Hermann Brenner
German Cancer Research Center
Isabelle Soerjomataram
Centre international de recherche sur le cancer
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”